Cargando…

Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis

BACKGROUND & AIMS: Compositional changes of the faecal microbiome in cirrhosis are well described and have been associated with complications and prognosis. However, it is less well known, which disease or treatment‐related factors affect microbiome composition most distinctively. METHODS: 16S r...

Descripción completa

Detalles Bibliográficos
Autores principales: Stadlbauer, Vanessa, Komarova, Irina, Klymiuk, Ingeborg, Durdevic, Marija, Reisinger, Alexander, Blesl, Andreas, Rainer, Florian, Horvath, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187411/
https://www.ncbi.nlm.nih.gov/pubmed/31943691
http://dx.doi.org/10.1111/liv.14382
_version_ 1783527169868169216
author Stadlbauer, Vanessa
Komarova, Irina
Klymiuk, Ingeborg
Durdevic, Marija
Reisinger, Alexander
Blesl, Andreas
Rainer, Florian
Horvath, Angela
author_facet Stadlbauer, Vanessa
Komarova, Irina
Klymiuk, Ingeborg
Durdevic, Marija
Reisinger, Alexander
Blesl, Andreas
Rainer, Florian
Horvath, Angela
author_sort Stadlbauer, Vanessa
collection PubMed
description BACKGROUND & AIMS: Compositional changes of the faecal microbiome in cirrhosis are well described and have been associated with complications and prognosis. However, it is less well known, which disease or treatment‐related factors affect microbiome composition most distinctively. METHODS: 16S rDNA sequencing data of 88 cirrhotic outpatients were investigated. Factors influencing microbiome composition were analysed by univariate and multivariate redundancy analysis. The association of the identified factors with changes in diversity and taxonomic composition was studied in depth using analysis of composition of microbiome, LDA‐effect size and least absolute shrinkage and selection operator regularized regression. RESULTS: Disease severity and aetiology, proton pump inhibitor (PPI) use, nutritional status, age and C‐reactive protein are significant explanatory variables for faecal microbiome composition in liver cirrhosis. Despite some taxonomic overlaps especially between disease severity and PPI use, we could show that the effects of disease severity, aetiology, PPI use and age are independent factors influencing microbiome composition also in subgroup analyses. CONCLUSION: Our cross sectional system biology study identifies disease severity, aetiology, PPI use and age as independent factors that influence microbiome composition in liver cirrhosis. In chronic diseases with high morbidity, such as liver cirrhosis, precise patient metadata documentation is of utmost importance in microbiome analysis. Further studies with a higher sample size are necessary to validate this finding. Trial Registration Number: NCT01607528
format Online
Article
Text
id pubmed-7187411
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71874112020-04-28 Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis Stadlbauer, Vanessa Komarova, Irina Klymiuk, Ingeborg Durdevic, Marija Reisinger, Alexander Blesl, Andreas Rainer, Florian Horvath, Angela Liver Int Gut‐liver Axis, Immunology, Immune Mediated and Cholestatic Diseases BACKGROUND & AIMS: Compositional changes of the faecal microbiome in cirrhosis are well described and have been associated with complications and prognosis. However, it is less well known, which disease or treatment‐related factors affect microbiome composition most distinctively. METHODS: 16S rDNA sequencing data of 88 cirrhotic outpatients were investigated. Factors influencing microbiome composition were analysed by univariate and multivariate redundancy analysis. The association of the identified factors with changes in diversity and taxonomic composition was studied in depth using analysis of composition of microbiome, LDA‐effect size and least absolute shrinkage and selection operator regularized regression. RESULTS: Disease severity and aetiology, proton pump inhibitor (PPI) use, nutritional status, age and C‐reactive protein are significant explanatory variables for faecal microbiome composition in liver cirrhosis. Despite some taxonomic overlaps especially between disease severity and PPI use, we could show that the effects of disease severity, aetiology, PPI use and age are independent factors influencing microbiome composition also in subgroup analyses. CONCLUSION: Our cross sectional system biology study identifies disease severity, aetiology, PPI use and age as independent factors that influence microbiome composition in liver cirrhosis. In chronic diseases with high morbidity, such as liver cirrhosis, precise patient metadata documentation is of utmost importance in microbiome analysis. Further studies with a higher sample size are necessary to validate this finding. Trial Registration Number: NCT01607528 John Wiley and Sons Inc. 2020-01-24 2020-04 /pmc/articles/PMC7187411/ /pubmed/31943691 http://dx.doi.org/10.1111/liv.14382 Text en © 2020 The Authors. Liver International published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Gut‐liver Axis, Immunology, Immune Mediated and Cholestatic Diseases
Stadlbauer, Vanessa
Komarova, Irina
Klymiuk, Ingeborg
Durdevic, Marija
Reisinger, Alexander
Blesl, Andreas
Rainer, Florian
Horvath, Angela
Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis
title Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis
title_full Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis
title_fullStr Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis
title_full_unstemmed Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis
title_short Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis
title_sort disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis
topic Gut‐liver Axis, Immunology, Immune Mediated and Cholestatic Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187411/
https://www.ncbi.nlm.nih.gov/pubmed/31943691
http://dx.doi.org/10.1111/liv.14382
work_keys_str_mv AT stadlbauervanessa diseaseseverityandprotonpumpinhibitoruseimpactstrongestonfaecalmicrobiomecompositioninlivercirrhosis
AT komarovairina diseaseseverityandprotonpumpinhibitoruseimpactstrongestonfaecalmicrobiomecompositioninlivercirrhosis
AT klymiukingeborg diseaseseverityandprotonpumpinhibitoruseimpactstrongestonfaecalmicrobiomecompositioninlivercirrhosis
AT durdevicmarija diseaseseverityandprotonpumpinhibitoruseimpactstrongestonfaecalmicrobiomecompositioninlivercirrhosis
AT reisingeralexander diseaseseverityandprotonpumpinhibitoruseimpactstrongestonfaecalmicrobiomecompositioninlivercirrhosis
AT bleslandreas diseaseseverityandprotonpumpinhibitoruseimpactstrongestonfaecalmicrobiomecompositioninlivercirrhosis
AT rainerflorian diseaseseverityandprotonpumpinhibitoruseimpactstrongestonfaecalmicrobiomecompositioninlivercirrhosis
AT horvathangela diseaseseverityandprotonpumpinhibitoruseimpactstrongestonfaecalmicrobiomecompositioninlivercirrhosis